Category: Natural killer cells
-
The June 2025 update to TAG’s listing features 11 changes. New Additions Two studies were added: The ACTG has registered a new trial of dual broadly neutralizing antibodies (bNAbs), VRC07-523LS and PGT121.414.LS, in people who initiated antiretroviral therapy (ART) during acute HIV infection. The protocol includes an analytical treatment interruption (ATI) to assess whether receipt…
-
A total of eight changes were made to TAG’s listing for the first monthly update of 2024. New Additions One new study has been added from the Pan African Clinical Trials Registry: Scientists affiliated with the Centre for the AIDS Programme of Research in South Africa (CAPRISA) are launching a phase I cure-related trial investigating…
-
No new HIV cure-related trials or studies were added to the clinicaltrials.gov registry over the past month. A total of seven updates were made to TAG’s listing: A clinical trial in Barcelona, Spain investigating the effects of the drug dasatinib on HIV persistence and inflammation is now open for enrollment. Dasatinib is a tyrosine kinase…
-
No new HIV cure-related trials or studies have been added to the clinicaltrials.gov registry over the past month. Two trials in the listing have changed status: A study sponsored by the ANRS in France investigating the link between specific immune system genetics (MHC B35/53Bw4TTC2) and post-treatment control of HIV is now open for enrollment. Participants…
-
The April 2023 update to TAG’s HIV cure-related clinical research listing adds five new studies, two involving interventions and three observational. Researchers at the University of Sao Paulo General Hospital in Brazil are opening a study of a therapeutic HIV vaccine based on dendritic cells (DCs). DCs are immune system cells tasked with initiating the…
-
The February 15, 2023 update to TAG’s HIV cure-related clinical research listing includes three newly registered studies: The AIDS Clinical Trials Group (ACTG) is initiating a study of two long-acting broadly neutralizing antibodies (bNAbs) named VRC07-523LS and PGT121.414.LS combined with antiretroviral therapy (ART) in people with acute (recently acquired) HIV infection. The trial has yet…
-
The 24th International AIDS Conference (AIDS 2022) officially opens on Friday in Montreal, but a Zoom press conference today shared news of results from several studies, including two case reports relevant to HIV cure research. Jana Dickter from the City of Hope hospital in Los Angeles described another instance of “prolonged HIV-1 remission” after receipt…
-
Among the most newsworthy presentations at CROI 2018 earlier this year was Dan Barouch’s description of a study involving a toll-like receptor 7 (TLR7) agonist combined with a broadly neutralizing antibody (bNAb) in SHIV-infected macaques (see contemporary coverage by AIDSMap, i-Base and POZ Magazine). The results have now been published in the journal Nature. The…
-
In the aftermath of the 22nd International AIDS Conference (AIDS 2018), which took place in Amsterdam in July, there has been some reflecting on the challenges facing the HIV cure research field. The presentations that garnered the most news coverage described disappointing study results, but there were also nuggets of novelty and encouragement to be…
-
Over the past few months, several interesting papers addressing elite control of HIV infection have seen publication. The ability of elite controllers to maintain undetectable viral loads and relatively preserved CD4 T cell counts in the absence of ART has led them to be proposed as a model for a functional cure of HIV infection.…